Gyre Therapeutics (GYRE) AI Stock Analysis

• Market Cap: $987.61M
• Dividend Yield: N/A
• Average Volume (3M): 115.02K
• Price to Earnings (P/E): 234.0
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 579
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 88,101,040
• 10 Day Avg. Volume: 107,310
• 30 Day Avg. Volume: 115,016
• PEG Ratio: 0.51
• Price to Book (P/B): 12.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -149.99
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 2.00
• Enterprise Value/Gross Profit: 8.67
• Enterprise Value/Ebitda: 15.84
• 1Y Price Target: $20.00
• Price Target Upside: 130.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: $11.50 ▲( 32.49% Upside)

The overall stock score for Gyre Therapeutics is driven primarily by recent positive corporate events, which highlight significant strategic progress and potential market impact. However, this is offset by financial performance challenges, particularly in cash flow and valuation concerns due to a high P/E ratio. Technical analysis suggests some positive momentum, but these factors are secondary to the strategic developments.

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

How the Company Makes Money

null

Gyre Therapeutics Financial Statement Overview

Summary

Gyre Therapeutics shows mixed financial performance. While operational efficiencies have improved as reflected in better EBIT and EBITDA margins, revenue growth is volatile. The balance sheet is strengthening with a solid equity base, but past volatility in equity levels poses a risk. Liquidity challenges are evident with negative free cash flow and inconsistent operating cash flow.

Income Statement

Gyre Therapeutics has shown inconsistent revenue growth, with a significant drop from 2023 to 2024. The gross profit margin remains high, indicating efficient production costs, but the net profit margin is volatile due to fluctuating net income. The EBIT and EBITDA margins have improved over the years, reflecting some stabilization in operational efficiency.

Balance Sheet

The company's balance sheet shows a strong equity base as of 2024, with a favorable debt-to-equity ratio indicating low leverage. However, the past volatility in stockholders' equity, including negative equity in 2023, could pose a risk. The equity ratio is strong, showing a good proportion of assets financed by equity.

Cash Flow

Cash flow from operations has been inconsistent, with a significant negative figure in 2024. Free cash flow has also been negative, raising concerns about liquidity. The operating cash flow to net income ratio is concerning due to negative operating cash flow, indicating potential cash management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
105.76M	113.45M	794.00K	7.34M	20.95M
	Gross Profit
101.87M	108.81M	-4.00K	-42.00K	11.79M
	EBIT
16.16M	-67.23M	-8.61M	-87.89M	-57.37M
	EBITDA
17.82M	20.33M	10.33M	-87.60M	-57.37M
	Net Income Common Stockholders
12.09M	-92.93M	2.30M	-87.93M	-55.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
26.67M	33.51M	21.67M	46.85M	79.35M
	Total Assets
125.41M	116.54M	28.44M	55.66M	94.85M
	Total Debt
1.60M	409.00K	38.00K	2.38M	1.64M
	Net Debt
-10.21M	-33.10M	-21.63M	-41.96M	-28.72M
	Total Liabilities
27.00M	38.06M	50.13M	14.57M	18.78M
	Stockholders Equity
63.32M	-15.83M	-21.69M	41.09M	76.07M
Cash Flow		Free Cash Flow
-5.96M	17.31M	-38.09M	-84.59M	-55.31M
	Operating Cash Flow
-3.64M	25.89M	-33.10M	-83.75M	-55.05M
	Investing Cash Flow
-19.88M	-19.76M	55.43M	48.19M	9.66M
	Financing Cash Flow
2.10M	2.50M	-45.01M	49.55M	60.38M

Gyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Negative. The current price of 8.68 is below the 20-day moving average (MA) of 10.02, below the 50-day MA of 9.18, and below the 200-day MA of 11.47, indicating a bearish trend. The MACD of 0.39 indicates Positive momentum. The RSI at 43.03 is Neutral, neither overbought nor oversold. The STOCH value of 48.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GYRE.

Gyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	63 Neutral	$773.55M	―	222.83%	―	29.88%	35.11%
NTLA	54 Neutral	$979.90M	―	-57.92%	―	-13.37%	2.57%
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
GYRE	52 Neutral	$987.61M	234.03	11.62%	―	―	―
ABCL	47 Neutral	$596.97M	―	-15.59%	―	-35.41%	-12.26%
NRIX	47 Neutral	$741.01M	―	-64.16%	―	-30.25%	-5.92%
PHVS	42 Neutral	$893.14M	―	-51.85%	―	―	0.71%

Gyre Therapeutics Corporate Events

Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial

On May 22, 2025, Gyre Therapeutics announced that its lead compound, Hydronidone, achieved the primary endpoint in a pivotal Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B in China. The 52-week trial demonstrated a statistically significant regression in liver fibrosis with Hydronidone compared to placebo, showing favorable safety and tolerability. This milestone positions Hydronidone as a potential first-in-class therapy for CHB-associated liver fibrosis, with plans for regulatory submission in China and further trials in the U.S.

The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Gyre Therapeutics Highlights Fibrosis Treatment Strategy

On April 28, 2025, Gyre Therapeutics released an updated corporate presentation highlighting its pioneering efforts in fibrosis treatment. The presentation detailed the company’s robust pipeline, including its lead asset F351, which targets chronic hepatitis B-related liver fibrosis, a significant unmet medical need in China. Gyre’s strategic approach involves a China-first validation strategy to leverage faster patient enrollment and cost efficiency, followed by expansion into the U.S. This strategy aims to mitigate clinical and regulatory risks while maintaining market leadership since the commercialization of pirfenidone in 2014.